The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States
Open accessAbstract
BACKGROUND: Neoadjuvant chemotherapy (NAC) is the standard of care for patients with locally advanced breast cancer and can yield clinical advantages in individuals with lower stage cancers as well. To the authors' knowledge, the extent and patterns of use of NAC remain unknown. The objective of the current study was to assess temporal trends in NAC use and to examine what clinical, demographic, and treatment site characteristics influence its use. METHODS: Data from the National Cancer Data Base regarding 395,486 patients with stage I to stage III breast cancer who received adjuvant or neoadjuvant chemotherapy in the United States from 2003 through 2011 were analyzed. Chi‐square tests and logistic regression analyses were used to assess the association between NAC use and patient, tumor, and facility characteristics. RESULTS: Overall, 17.4% of patients received NAC, including 4% of patients with stage I disease, 17.8% of patients with stage II disease, and 41.6% of patients with stage III disease. NAC use increased over time from 12.2% to 24.0%, particularly among patients with more advanced cancers. Rates increased from 12.9% to 39.3% in patients with stage IIIA, from 72.3% to 86.4% in patients with stage IIIB, and from 30.1% to 59.3% in patients with stage IIIC cancers. On multivariate analysis, patients aged <60 years, African American individuals, and those treated in academic centers were more likely to receive NAC. NAC use also varied by geographic region and was the highest in the West South Central region (21%) and lowest in the Midwest (15.2%). CONCLUSIONS: Although NAC use increased between 2003 and 2011, <50% of all patients with stage III breast cancer were treated with NAC. Substantial regional and practice‐related variations exist. Cancer 2015;121:2544–2552. © 2015 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789 · cited 1×
“For some of these patients, the use of NAC can lead to increased breast conservation rates, and even among patients who are eligible for breast conservation at the time of diagnosis, NAC may allow for a smaller surgical resection volume.(2-4) Regardless of tumor size, NAC also provides an opportunity to directly asses…”
Background
Cited by
Asselain, B., Barlow, W., Bartlett, J., Bergh, J., Bergsten-Nordström, E., Bliss, J., Boccardo, F., Boddington, C., Bogaerts, J., Bonadonna, G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30777-5 · Cited by 1,118
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Joo, S., Ko, E. S., Kwon, S., Jeon, E., Jung, H., Kim, J.-Y., Chung, M. J., & Im, Y.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-98408-8 · Cited by 137
Metadata
- Authors
- Mougalian, S. S., Soulos, P. R., Killelea, B. K., Lannin, D. R., Abu‐Khalaf, M. M., DiGiovanna, M. P., Sanft, T. B., Pusztai, L., Gross, C. P., & Chagpar, A. B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2015-04-22
- Volume
- 121
- Issue
- 15
- Pages
- 2544-2552
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1555003755
- Cited by
- 237
- References
- 1
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. https://app.cochat.ai/papers/10.1002/cncr.29348
- The paper
- Mougalian, S. S., Soulos, P. R., Killelea, B. K., Lannin, D. R., Abu‐Khalaf, M. M., DiGiovanna, M. P., Sanft, T. B., Pusztai, L., Gross, C. P., & Chagpar, A. B. (2015). Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. https://doi.org/10.1002/cncr.29348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.